NEW YORK (360Dx) – NeoGenomics has signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program, also referred to as COEP. NeoGenomics is one of the first laboratories to offer the newly US Food and Drug Administration-approved Oncomine Dx Target Test for non-small cell lung cancer. This methodology allows rapid analysis of samples compared to previously approved testing approaches. NeoGenomics' Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.